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Abstract 
Background: Discriminating between autoimmune pancreatitis (AIP), chronic pancreatitis (CP), and pancreatic 
ductal adenocarcinoma (PDAC) can be challenging. In this retrospective study, levels of serum and tissue cytokines 
were analyzed as part of the clinical strategy for the preoperative differentiation between AIP and PDAC. The identifi‑
cation of differential cytokine profiles may help to prevent unnecessary surgical resection and allow optimal treat‑
ment of these pathologies.
Methods: To compare the cytokine profiles of AIP, CP, and PDAC patients, serum and pancreatic tissue homogenates 
were subjected to multiplex analysis of 17 inflammatory mediators. In total, serum from 73 patients, composed of 29 
AIP (14 AIP‑1 and 15 AIP‑2), 17 CP, and 27 PDAC, and pancreatic tissue from 36 patients, including 12 AIP (six AIP‑1 and 
six AIP‑2), 12 CP, and 12 PDAC, were analyzed.
Results: Comparing AIP and PDAC patients’ serum, significantly higher concentrations were found in AIP for interleu‑
kins IL‑1β, IL‑7, IL‑13, and granulocyte colony‑stimulating factor (G‑CSF). G‑CSF also allowed discrimination of AIP from 
CP. Furthermore, once AIP was divided into subtypes, significantly higher serum levels for IL‑7 and G‑CSF were meas‑
ured in both subtypes of AIP and in AIP‑2 for IL‑1β when compared to PDAC. G‑CSF and TNF‑α were also significantly 
differentially expressed in tissue homogenates between AIP‑2 and PDAC.
Conclusions: The cytokines IL‑1β, IL‑7, and G‑CSF can be routinely measured in patients’ serum, providing an elegant 
and non‑invasive approach for differential diagnosis. G‑CSF is a good candidate to supplement the currently known 
serum markers in predictive tests for AIP and represents a basis for a combined blood test to differentiate AIP and 
particularly AIP‑2 from PDAC, enhancing the possibility of appropriate treatment.
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Background
Autoimmune pancreatitis (AIP) is an immune-mediated 
fibro-inflammatory form of pancreatitis that has a unique 
histopathologic pattern characterized by periductal lym-
phoplasmocytic infiltration, storiform fibrosis, and oblit-
erative phlebitis, which makes it distinguishable from 
other pancreas diseases [1, 2]. AIP, due to its immuno-
logical etiology, is the only type of pancreatitis that is 
responsive to steroid treatment [3, 4]. Nowadays, two 
types of AIP exist, defined by distinct histology and clini-
cal profiles [5]. Furthermore there are differences in age 
of appearance [1, 2], sex ratio [1, 6–8], geographic distri-
bution [5], and histological, immunological, and imaging 
features [2, 6–10].
AIP type 1 (AIP-1) (the most common type in Asia), 
also named lymphoplasmocytic sclerosing pancreatitis 
(LPSP) because of its histological features, is associated 
with elevated IgG4 serum levels and IgG4-positive 
cell infiltration, an increased number of various 
autoantibodies [2, 6, 9], and involvement of other 
organs, such as peritoneum, biliary tract etc., besides the 
pancreas, reflecting a systemic disease [11].
AIP type 2 (AIP-2), called idiopathic duct-centric 
pancreatitis (IDCP), is recognized by its specific 
histological feature: granulocytic epithelial lesions (GEL) 
[1, 2, 6, 12]. These lesions consist of a focal disruption 
and destruction of the duct epithelium caused by the 
invasion of neutrophilic granulocytes, which makes some 
people call it AIP with GEL. It is likely that deregulated 
cytokines and other transcription factors are the driving 
force by which neutrophils are recruited to the ductal 
and acinar cells with subsequent destruction. This latter 
subtype is more common in Western countries [5].
The etiology and pathophysiological mechanisms of AIP 
remain unknown but several findings suggest that an auto-
immune mechanism might be involved, mainly because 
AIP is associated with hypergammaglobulinemia [2, 13] 
and increased levels of IgG4 in AIP-1 [2, 14, 15]. Addition-
ally, high titers of circulating immune complexes, an ele-
vated number of regulatory T cells (Tregs) in the tissue and 
blood of affected individuals [16, 17], and the presence of 
autoantibodies support the hypothesis of an autoimmune 
mechanism [18–20]. Finally, common association with other 
autoimmune diseases [11] and positive response to steroid 
therapy [3, 4] strengthen this theory. Cytokines are key medi-
ators of innate and adaptive immunity. They regulate a large 
spectrum of processes including antigen presentation, bone 
marrow differentiation, and cellular activation [21]. Due to 
their implication in various pathologies including cancer and 
inflammatory diseases, expression of different cytokines has 
been assessed in order to explain the inflammatory process 
involved in AIP [22–24].
Most autoimmune diseases are known to have a Th1-
predominant cytokine expression. However, in AIP both 
Th1 and Th2 cytokines have been described. Zen et  al. 
showed overexpression of Th2 and regulatory cytokines 
in the tissue of patients with autoimmune pancreato-
cholangitis [25], while Okazaki et  al. [20] demonstrated 
an increase of Th1 cytokines in the peripheral blood of 
patients suffering from AIP. However, the lack of differ-
entiation between AIP-1 and AIP-2 among AIP patients 
in the currently published data makes the interpretation 
of these studies very difficult.
Distinction between AIP subtypes from pancreatic 
ductal adenocarcinoma (PDAC) is difficult and 
clinically relevant since they require different treatment. 
Nowadays, different tools such as serological markers 
and imaging features can help, but still are not sufficient 
to discriminate accurately the diseases [26]. Currently, 
about 2.2 to 3.7% of patients undergoing surgery for 
suspected pancreatic cancer turn out to have AIP [27–
29]. Furthermore, in an international multicenter survey, 
it was shown that 60% (123 of 204) and 78% (50 of 64) 
of AIP-1 and AIP-2 patients, respectively, were evaluated 
retrospectively from cases resected on suspicion of 
pancreatic cancer [5]. The need for new diagnostic tools 
is crucial to decrease these numbers.
The aim of the present investigation was to assess and 
compare expression profiles of different cytokines in 
serum and pancreatic tissue of both AIP subtypes and 
compare their levels with pancreatic cancer (PDAC) and 
chronic pancreatitis (CP).
Methods
Patients and samples
Banked serum (drawn upon admission or prior to 
surgery) and pancreatic tissue samples (obtained during 
surgery) were collected between 2001 and 2009, in the 
Biobank of the European Pancreas Center, Department 
of Surgery, Heidelberg University Hospital, Heidelberg. 
All sera were stored at −80 °C. Age, pathologic diagnosis, 
and serological analyses at the time of sample acquisition 
were obtained for all groups. Prior to analysis, all 
pancreatic tissues were reviewed by a pathologist to 
confirm disease diagnosis (AIP-1, AIP-2, CP, and PDAC).
Serum cytokine multiplexing
Sera included specimens from 29 AIP patients. Among 
them, 23 underwent pancreatic surgery, and histology 
confirmed the disease. Six patients were diagnosed 
according to the HISORt Mayo Clinic criteria [30] and 
by the effectiveness of steroid treatment. The CP and 
PDAC groups consisted of 17 and 27 serum samples, 
respectively (Table 1a).
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Pancreatic tissue homogenate cytokine multiplexing
The total of 36 pancreatic tissue samples investigated in 
this approach was composed of 12 AIP, 12 CP, and 12 
PDAC. Patients’ data are presented in Table 1b.
Multiplex cytokine analysis
A multiplex assay for simultaneous quantitative 
determination of proteins in diverse and complex 
biofluids was applied to assess concentrations of the 
selected cytokines in serum and tissue samples. The 
analysis was performed using the Bio-Plex Pro Human 
Cytokine 17-Plex panel (Bio-Rad Laboratories GmbH, 
Munich, Germany), a kit composed of 17 determinants. 
The following cytokines were simultaneously detected 
and standard curve range and limit of detection (LOD) 
all expressed in pg/ml are shown in parenthesis: IL-1β 
(0.34–4.991; LOD 0.06), IL-2 (2.27–9.531; LOD 0.62), 
IL-4 (0.22–3.207; LOD 0.15), IL-5 (3.25–13.069; LOD 
2.3), IL-6 (1.41–23.178; LOD 0.61), IL-7 (0.68–11.063; 
LOD 0.66), IL-8 (1.38–2.183; 0.95), IL-10 (3.39–5.521; 
LOD 0.22), IL-12 (2.35–38.575; LOD 0.29), IL-13 
(0.36–5.908; LOD 0.19), IL-17 (2.00–32.716; LOD 0.68), 
G-CSF (1.73–28.267; LOD 1.47), GM-CSF (2.45–10.848; 
LOD 1.47), IFN-γ (2.57–14.845; LOD 0.96), MCP-1 
(3.72–55.124; LOD 2.65), MIP-1β (1.134–4.543; LOD 
1.06), and TNF-α (3.18–52.115; LOD 1.88). A series of 
calibrators was analyzed with the patient samples to 
convert the fluorescence ratio to international units per 
milliliter. Concentration of each analyte was obtained by 
interpolating fluorescence intensity to eight-point dilution 
standard curve supplied by the kit. Values that were 
outside the standard curve range were calculated by the 
Brendan Scientific weighted five parameter fit algorithm 
as best estimation of the analyte concentrations within 
the samples and were obtained by extrapolation beyond 
the dynamic range of the standard curve and calculated 
by the Bio-Plex™ software (Bio-Plex Manager version 6.1 
BioRad). All serum samples were measured in triplicate.”
Multiplexing was performed according to the 
manufacturer’s instruction manual. Briefly, for cytokine 
determination in serum, magnetic beads coated with 
antibodies against the examined antigens were mixed 
with 200 μl of each 1 : 4 v/v diluted patient sample (50 µl 
serum and 150  µl dilution buffer, Bio-Rad) and then 
incubated for 30  min. After a wash cycle followed by 
the addition of a detection antibody, another 30  min 
incubation, and a second wash cycle, streptavidin-PE 
was added to the beads. With the third wash cycle the 
excess conjugate was removed, and the bead mixture was 
analyzed on a Bio-Rad Bio-Plex 200 system.
For cytokine determination in pancreatic tissue, 
60–80  mg of frozen tissue samples was cut with a cry-
omicrotome into 9  μm-thick slices (Leica CM 3050 S 
Leica Biosystems, Nussloch, Germany), collected in 15 ml 
polypropylene tubes, and mixed with 500 µl of lysis buffer 
(Bio-Rad). Each tube was vigorously vortexed then shock-
frozen in liquid nitrogen and stored overnight at −80 °C. 
The day after, using an ultrasonic homogenizer (SonoPuls 
mini20  Bandelin®, Berlin, Germany), the suspensions 
were subjected to a 30  s sonication step on ice (ampl. 
80%, 0.99  kJ) and subsequently centrifuged at 16,000×g 
for 10 min. Supernatants were collected and divided into 
aliquots, and the total protein concentration was deter-
mined using a Pierce BCA assay (Thermo, Rockford, IL, 
USA). For multiplexing, the supernatants were adjusted 
with a dilution buffer (Bio-Rad) to a total protein concen-
tration of 600 μg/ml and analyzed using the Bio-Plex Pro 
Human Cytokine 17-Plex panel kit (Bio-Rad) according to 
the manufacturer’s protocol as described above.
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism software (version 5; La Jolla, CA, USA) and IBM 
SPSS Statistics version 22 (IBM Corp, Armonk, NY, 
USA). As variables were not normally distributed, the 
nonparametric Mann–Whitney test was used to assess 
the significant differences in multiplexing assays of 
serum and tissue extracts. The quantitative variables are 
graphically presented as box-and-whisker plots. Values of 
p ≤ 0.05 were considered to be significant. All tests were 
used two-sided.
Receiver operating characteristic (ROC) curves were 
calculated to analyze the test performance of serum 
cytokines G-CSF and IL-7 for predicting AIP using SAS 
software (release 9.4, SAS Institute, Inc., Cary, NC, USA). 
Logistic regression analysis was performed to gener-
ate sensitivity, specificity, and area under curve (AUC) 
Table 1 Patient data on samples used for serum and tissue 
extracts cytokine evaluation approaches
IQR inter quartile range
Total AIP-1 AIP-2 CP PDAC
a Serum cytokine multiplexing
 Patients [n] 73 14 15 17 27
 Male [n] (%) 50 (68.5) 14 (100) 11 (73.3) 162 (70.6) 13 (48.1)
 Median age 
(IQR)
58.0 (21) 56.5 (21.3) 44.0 (25) 55.0 (16.5) 61.0 (13)
b Pancreatic tissue homogenate cytokine multiplexing
 Patients [n] 36 6 6 12 12
 Male [n] (%) 28 (77.8) 6 (100) 5 (83.3) 8 (66.7) 9 (75)
 Median age 
(IQR)
54.0 (21) 54.0 (12.0) 40.5 (21.25) 51.0 (12.5) 69.5 (24)
Page 4 of 11Ghassem‑Zadeh et al. J Transl Med  (2017) 15:126 
values. Youden’s J statistic was used to select the optimal 
predicted probability cut-off.
Results
Serum cytokine profiling
All the comparisons on different cytokines were executed 
twice. At first, evaluations were performed between 
all AIP vs PDAC and CP patients and the reference 
category was always AIP. The comparison of serum 
cytokine expression levels in the three different groups is 
summarized in Table 2. The statistical analysis of serum 
comparing AIP to PDAC revealed a significantly higher 
concentration in AIP patients for IL-1β (p = 0.0221), for 
IL-7 (p = 0.0003), for IL-13 (p = 0.0337), and for G-CSF 
(p = 0.0105). The G-CSF levels in AIP (median 14.23 pg/
ml) were also significantly discriminatory between AIP 
and CP (1.47 pg/ml) (p = 0.0006).
Subsequently, comparisons were performed among 
the AIP-1, AIP-2, PDAC, and CP groups using AIP-1 
and AIP-2 separately as reference categories. When 
AIP-1, AIP-2, CP, and PDAC were compared and AIP-1 
was used as a reference category, significantly higher 
concentrations of IL-7 (p = 0.0012), IL-13 (p = 0.0162), 
and G-CSF (p = 0.0425) were found in AIP-1 compared 
to PDAC. Also, a significantly higher level of G-CSF 
(p  =  0.0039) in AIP-1 compared to CP was noticed. 
When we compared AIP-2 with PDAC, we found sig-
nificantly higher levels of IL-1β (p  =  0.0217), IL-7 
(p = 0.005), and G-CSF (p = 0.032) in AIP-2. Comparing 
AIP-2 with CP, significantly higher levels in AIP-2 were 
found for IL-6 (p = 0.0361), for IL-17 (p = 0.0377), and 
G-CSF (p =  0.0034). The range of cytokine distribution 
in the analyzed groups is presented in Fig. 1a–i and the 
median concentrations with the IQR of analyzed samples 
are summarized in Additional file 1: Table S1.
In order to evaluate the diagnostic utility of cytokines 
IL-7 and G-CSF for predicting AIP, a ROC curve analy-
sis was carried out using the AIP, CP, and PDAC cytokine 
serum data. The obtained results are summarized in 
Table 3. IL-7 discriminated better than G-CSF AIP from 
PDAC (AUC of 0.780 vs 0.686). Combination of both IL-7 
and G-CSF for differentiation only marginally improved 
the diagnostic value of the two markers (AUC =  0.782) 
as presented in Fig. 2; addition of IL-1β showed no fur-
ther improvement (results not shown). Of note, the com-
parison between patients with CP and those with AIP, 
G-CSF alone performed better (AUC =  0.804) than the 
combination of both G-CSF and IL-7 (AUC  =  0.787). 
Using G-CSF as reference curve the differences in the 
AUC reached significance in the AIP vs. CP comparisons 
(p = 0.0052) but not in the AIP vs PDAC using G-CSF as 
reference curve (p = 0.395).
Pancreatic tissue cytokine profiling
Similarly to the serum cytokine profiling, a tissue 
homogenate analysis was performed. The levels of 
cytokines in CP, PDAC, and both AIP forms were com-
pared. Here, significantly higher concentrations (9.56 pg/
Table 2 Comparison of cytokine levels in serum from: AIP, CP and PDAC patients
Italic values indicate significance of p value (p < 0.05)
IQR interquartile range, n number of observations
Cytokine Compared groups
1st group vs 2nd group
Median conc. (pg/ml)
of 1st group/IQR/n
Median conc. (pg/ml)
of 2nd group/IQR/n
p-value
IL‑1β AIP vs CP
AIP vs PDAC
0.58/0.86/29
0.58/0.86/29
0.39/1.3/17
0.39/0.55/27
0.5193
0.0221
IL‑6 AIP vs CP
AIP vs PDAC
12.58/18.76/28
12.58/18.76/28
1.44/25.63/17
10.89/22.42/27
0.1399
0.4435
IL‑7 AIP vs CP
AIP vs PDAC
13.70/8.22/29
13.70/8.22/29
8.72/13.04/17
8.27/3.65/27
0.1386
0.0003
IL‑8 AIP vs CP
AIP vs PDAC
22.64/13.05/29
22.64/13.05/29
17.17/23.77/17
21.56/26.87/27
0.2410
0.4806
IL‑10 AIP vs CP
AIP vs PDAC
2.68/12.91/28
2.68/12.91/28
0.40/12.10/13
4.09/9.59/21
0.0792
0.9919
IL‑13 AIP vs CP
AIP vs PDAC
0.32/0.70/27
0.32/0.70/27
0.32/1.95/17
0.13/0.28/26
0.5025
0.0337
IL‑17 AIP vs CP
AIP vs PDAC
7.44/19.27/29
7.44/19.27/29
0.03/10.35/17
4.32/19.31/27
0.1239
0.5937
G‑CSF AIP vs CP
AIP vs PDAC
14.23/16.85/29
14.23/16.85/29
1.47/3.93/17
5.23/13.82/27
0.0006
0.0105
MCP‑1 AIP vs CP
AIP vs PDAC
56.35/65.13/29
56.35/65.13/29
10.61/97.51/17
43.41/104.96/27
0.0738
0.3890
MIP‑1β AIP vs CP
AIP vs PDAC
130.02/65.10/29
130.02/65.10/29
96.66/62.28/17
122.72/83.47/27
0.0837
0.8956
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mg) of G-CSF (p  =  0.0138) were measured in AIP vs 
PDAC (3.44 pg/mg) and significantly lower levels were 
measured for IL-8 and TNF-α in the AIP group.
On the other hand, comparing the AIP and CP groups, 
AIP revealed significantly higher concentrations for IL-17 
(p =  0.0120) and MIP-1β (p =  0.0326) and lower levels 
of TNF-α (p = 0.0038). The median concentration values 
and IQR are presented in Table 4.
Subsequently, all groups were separately compared 
either with subgroup AIP-1 or with AIP-2. Cytokines 
with interesting differences between the analyzed groups 
are presented in Fig.  3a–k and Additional file  2: Table 
S2. Of note, both AIP subtypes were distinguished from 
another by two cytokines IL-8 (p  =  0.0152) and IFN-γ 
(p  =  0.0376) showing higher levels in the AIP-2 sub-
type. IL-10 also showed slightly higher levels in AIP-2 
(p = 0.0542).
Discussion
The role of cytokines and growth factors in the 
development and progression of pancreatic inflammatory 
diseases including cancer has been intensively studied 
over recent decades [31]. In this study we investigated the 
ability of a variety of inflammatory mediators to detect 
and discriminated AIP from the pancreatic diseases CP 
and PDAC. The expression profile of 17 cytokines was 
Fig. 1 Serum levels and distribution range of the most differentially expressed cytokines (a–i) from AIP‑1, AIP‑2, CP, and PDAC patients. Differences 
were considered statistically significant when the p value was less than 0.05 and are marked with an asterisk: *p < 0.05, **p < 0.01
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evaluated in the serum and pancreatic tissue extracts in 
both AIP forms, either as one entity or segregated into 
AIP-1 and AIP-2, and compared with the levels found 
in CP and PDAC. Significant differences in serum of 
patients’ with AIP and PDAC were found for IL-1β, IL-7, 
and G-CSF, all with higher levels in AIP. G-CSF also 
revealed to be a good discriminator between both AIP, 
respectively their subtypes compared to CP and PDAC 
(Fig.  1f ). This observation was also confirmed in the 
tissue extracts as shown in Fig. 3f.
We were able to demonstrate that IL-7 and G-CSF 
are valid serum markers for the differential diagnosis of 
AIP and PDAC. Combination of both cytokines revealed 
a slightly better differential diagnosis (AUC  =  0.782). 
Likewise G-CSF turned out to be a good discriminatory 
marker between AIP and CP (AUC = 0.804)
G-CSF is a hematopoietic growth factor that induces 
proliferation of hematopoietic and cancer cells. It has 
been reported in different cancers including pancreatic 
cancer [32, 33]. A subtype of PDAC, which produce high 
levels of G-CSF (approx. 7%), is thought to attract high 
amounts of neutrophils, which can behave deleterious 
and are associated with a poor patients’ prognosis [34, 
35]. In this study, we demonstrate for the first time the 
expression of G-CSF in AIP. It is known that different 
inflammatory stimuli such as IL-1β, IL-17, TNF-α, and 
lipopolysaccharide increase circulating levels of G-CSF 
that stimulate neutrophil production in the bone marrow 
[36, 37]. Interestingly, we found significantly higher 
expression of both IL-1β and G-CSF, which may be 
linked to a particular immune response linked to the AIP 
disease.
Interest in the functional effect of IL-7 in autoimmune 
diseases has grown in recent years due to the fact that 
enhanced IL-7 level fuels the proliferation of autoreactive 
T cells [38]. Given the role of IL-7 in T cell growth factor 
activity, it is not a surprise that increased levels of IL-7 
have been reported in several autoimmune diseases such 
as multiple sclerosis [39], rheumatoid arthritis [40], type 
1 diabetes [41], and systemic lupus erythematosus [42]. 
We also report here for the first time increased IL-7 
serum levels in patients suffering from AIP.
In this study, MIP-1β and IL-17 allowed discrimination 
of AIP-2 from CP. It is known that elevated numbers 
of Th-17 cells and IL-17 levels, found in the periductal 
compartiments, are linked to the destruction of the 
pancreatic duct epithelium in AIP-2 [43]. Supporting 
the deleterious behavior of IL-17 it has been shown that 
IL-17 intensifies the effects of proinflammatory cytokines 
such as TNF-α, IL-1β, and IL-6 [44], thus orchestrating 
the formation of neutrophil extracellular traps (NETs) 
and the occlusion of pancreatic ducts leading to 
pancreatic inflammation [45].
Furthermore, higher expression of TNF-α was 
observed in our PDAC tissue lysates compared to AIP-1 
and AIP-2 patients. It is well accepted that TNF-α 
induces pancreatic cancer cell proliferation [46]. TNF-α 
promotes the invasiveness of human pancreatic cancer 
cells and promotes tumor growth and metastasis in mice 
[31, 47].
As further finding, IL-8 and IFN-γ allowed 
discrimination between both AIP subtypes. These two 
cytokines were expressed in higher levels in the tissue 
of AIP-2 patients compared to these of AIP-1. IL-8 is a 
neutrophil-activating cytokine released from different 
cell types under inflammatory conditions [48]. IL-1 
and TNF-α are the predominant stimuli that induce 
monocytes and macrophages to generate IL-8 [49]. 
Regarding IL-8 function, it is not surprising that its 
concentration is increased in the pancreatic tissue of 
patients suffering from AIP-2 since one of the hallmarks 
of AIP-2 is the presence of neutrophils in the pancreatic 
duct epithelia. Altogether, IL-1β, IL-7, IL-17, and G-CSF 
levels are increased in the serum of AIP-2 and IL-8 and 
IFN-γ levels in the pancreatic tissues of AIP-2 showing 
the importance of neutrophils in the pathophysiology of 
pancreatic inflammation.
Conclusions
Clinically, it is of great relevance to distinguish PDAC 
from AIP. The significantly higher levels of IL-1β, 
IL-7, and G-CSF found in AIP-2 patients’ serum could 
be valuable markers in helping to distinguish it from 
PDAC. The results presented here show a high degree 
of reproducibility, particularly for G-CSF, providing 
reasons to prospectively evaluate this marker as a diag-
nostic tool. Currently, IgG4 is used as marker for AIP-1 
but AIP-2 lacks a serological biomarker. Additionally, 
in AIP-1 cases where IgG4 levels are not elevated, the 
two cytokines IL-7 and G-CSF differentiated these AIP 
Table 3 Diagnostic performance of  serum IL-7, G-CSF, 
and in combination G-CSF + IL-7 as biomarkers for differ-
ential diagnosis
Marker Sensitivity Specificity AUC
IL‑7 (cut off 10.02 pg/ml)
 AIP vs PDAC 77.78 75.86 0.780
 AIP vs CP 89.66 17.65 0.367
G‑CSF (cut off 9.92 pg/ml)
 AIP vs PDAC 68.97 70.37 0.686
 AIP vs CP 86.21 76.47 0.804
G‑CSF + Il‑7
 AIP vs PDAC 75.86 77.78 0.782
 AIP vs CP 86.21 76.47 0.787
Page 7 of 11Ghassem‑Zadeh et al. J Transl Med  (2017) 15:126 
Fig. 2 Receiver operator characteristic (ROC) analysis of serum IL‑7 and G‑CSF: a–c for differentiating patients with AIP from those with PDAC. a 
ROC curve for G‑CSF. b ROC curve for IL‑7, c ROC curve for combined index of G‑CSF and IL‑7. The respective areas under the curve (AUC) are 0.699 
for G‑CSF, 0.780 for IL‑7, and 0.782 for the combination of both. d ROC curve for G‑CSF for differentiating patients with AIP from those with CP 
(AUC = 0.804)
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patients from PDAC. Applying a multiplex ELISA for 
IL-1β, IL-7, and G-CSF on patients’ serum would also 
allow AIP-2 to be distinguished from PDAC. Combin-
ing them with the recently identified gelatinases A and 
B and apolipoproteins Apo-AI and Apo-AII as discrimi-
natory parameters [50–52] in a multiplex format, this 
could form the basis for a clinically applicable blood test, 
allowing reliable distinction between AIP and PDAC. 
This test would warrant immune-suppressive therapy 
without surgery for AIP patients and immediate surgi-
cal and chemotherapeutical treatment of PDAC patients. 
Wrong treatment of these modalities results in loss of 
Table 4 Cytokine levels in pancreatic tissue lysates from total AIP, CP and PDAC patients
Concentrations are expressed in pg/mg total protein
Italic values indicate significance of p value (p < 0.05)
IQR interquartile range, n number of observations
Cytokine Compared groups
1st group vs 2nd group
Median conc. (pg/mg)
of 1st group/IQR/n
Median conc. (pg/mg)
of 2nd group/IQR/n
p-value
IL‑1β AIP vs CP
AIP vs PDAC
2.69/4.57/12
2.69/4.57/12
1.71/1.31/12
2.01/4.29/12
0.1332
0.3708
IL‑6 AIP vs CP
AIP vs PDAC
12.82/40.48/11
12.82/40.48/11
12.62/28.80/12
40.6/73.42/12
0.8055
0.2549
IL‑7 AIP vs CP
AIP vs PDAC
2.9/1.72/11
2.9/1.72/11
4.46/2.08/12
4.01/4.28/12
0.1090
0.4036
IL‑8 AIP vs CP
AIP vs PDAC
17.82/338.64/12
17.82/338.64/12
27.25/70.63/12
105.30/138.65/12
0.9770
0.0304
IL‑10 AIP vs CP
AIP vs PDAC
0.59/0.72/12
0.59/0.72/12
1.05/0.63/12
0.92/0.51/12
0.0732
0.2713
IL‑13 AIP vs CP
AIP vs PDAC
4.7/7.15/11
4.7/7.15/11
8.87/8.01/12
8.56/5.81/12
0.0694
0.2064
IL‑17 AIP vs CP
AIP vs PDAC
21.93/27.03/12
21.93/27.03/12
10.64/12.12/12
21.2/25.98/11
0.0120
0.4789
G‑CSF AIP vs CP
AIP vs PDAC
9.56/11.67/12
9.56/11.67/12
1.98/8.64/12
3.44/7.40/12
0.1080
0.2790
IFN‑γ AIP vs CP
AIP vs PDAC
7.02/27.31/12
7.02/27.31/12
25.7/17.67/12
19.50/20.66/12
0.0815
0.2167
MCP‑1 AIP vs CP
AIP vs PDAC
303.70/509.70/12
303.70/509.70/12
158.94/206.72/12
140.45/286.84/12
0.1260
0.2145
MIP‑1 β AIP vs CP
AIP vs PDAC
224.20/354.68/12
224.20/354.68/12
90.17/132.30/12
112.90/277.46/12
0.0326
0.3708
TNF‑α AIP vs CP
AIP vs PDAC
6.01/2.89/12
6.01/2.89/12
12.60/10.13/12
8.97/17.84/12
0.0038
0.0086
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Fig. 3 Comparison of the concentrations of different cytokines (a–k) in pancreatic tissue extracts. Values are presented in pg of cytokine per mg 
of total protein. Differences were considered statistically significant when the p value was less than 0.05 and are marked with an asterisk: *p < 0.05, 
**p < 0.01, and ***p < 0.001
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precious time for cancer patients to obtain the right 
therapy and, on the other hand, causes AIP patients to 
undergo a huge operation, which is not necessary for 
this condition.
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